HC Wainwright restated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT – Free Report) in a report issued on Tuesday, Benzinga reports. HC Wainwright also issued estimates for RAPT Therapeutics’ Q3 2024 earnings at ($0.63) EPS, Q4 2024 earnings at ($0.57) EPS, Q1 2025 earnings at ($0.63) EPS, Q2 2025 earnings at ($0.65) EPS, Q3 2025 earnings at ($0.68) EPS, Q4 2025 earnings at ($0.62) EPS and FY2025 earnings at ($2.58) EPS.
A number of other research analysts also recently commented on the stock. Guggenheim downgraded shares of RAPT Therapeutics from a buy rating to a neutral rating in a research report on Friday, May 10th. Barclays downgraded shares of RAPT Therapeutics from an overweight rating to an equal weight rating and dropped their target price for the company from $13.00 to $4.00 in a research report on Friday, May 10th. Finally, Wolfe Research reaffirmed a peer perform rating on shares of RAPT Therapeutics in a research report on Tuesday, May 14th. Nine investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, RAPT Therapeutics presently has a consensus rating of Hold and a consensus price target of $21.57.
Get Our Latest Research Report on RAPT Therapeutics
RAPT Therapeutics Stock Performance
RAPT Therapeutics (NASDAQ:RAPT – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.03. As a group, analysts predict that RAPT Therapeutics will post -2.75 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of RAPT. Los Angeles Capital Management LLC purchased a new position in RAPT Therapeutics during the 4th quarter worth $233,000. Charles Schwab Investment Management Inc. grew its position in RAPT Therapeutics by 5.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 234,439 shares of the company’s stock worth $5,826,000 after purchasing an additional 12,650 shares during the last quarter. TimesSquare Capital Management LLC purchased a new position in RAPT Therapeutics during the 4th quarter worth $12,533,000. Chesapeake Capital Corp IL purchased a new position in RAPT Therapeutics during the 4th quarter worth $254,000. Finally, CenterBook Partners LP purchased a new position in RAPT Therapeutics during the 4th quarter worth $781,000. 99.09% of the stock is owned by hedge funds and other institutional investors.
RAPT Therapeutics Company Profile
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Further Reading
- Five stocks we like better than RAPT Therapeutics
- What does consumer price index measure?
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- How to Calculate Options Profits
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- 3 Small Caps With Big Return Potential
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.